SCHEMBL2228439

SCHEMBL2228439

O=C(Nc1ccc(-c2ccc3c(c2)C(=O)N([C@@H]2CCC[C@@H]2C(=O)O)C3)cc1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 6/20 0.46
LMNA P02545 1/20 0.45
RAB9A P51151 1/20 0.45
CSNK1A1 P48729 1/20 0.44
CRBN Q96SW2 1/20 0.44
DEGS1 O15121 1/20 0.43
PTPN1 P18031 3/20 0.43
KDM1A O60341 1/20 0.42
CREBBP Q92793 1/20 0.41
MCHR1 Q99705 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13718868 1.00 DGAT1 (0.46) DGAT1LMNARAB9ACSNK1A1CRBN
SCHEMBL2179473 0.93 DGAT1 (0.43) DGAT1RAB9AMCHR1
SCHEMBL2178972 0.93 DGAT1 (0.43) DGAT1RAB9AMCHR1
SCHEMBL2179639 0.91 DGAT1 (0.53) DGAT1RAB9AMCHR1
SCHEMBL2356973 0.91 DGAT1 (0.53) DGAT1RAB9AMCHR1
SCHEMBL13719434 0.86 KDM1A (0.44) DGAT1CSNK1A1CRBNDEGS1PTPN1
SCHEMBL13719196 0.83 KDM1A (0.45) CSNK1A1CRBNDEGS1PTPN1KDM1A
SCHEMBL13719179 0.83 KDM1A (0.45) CSNK1A1CRBNDEGS1PTPN1KDM1A
SCHEMBL2194255 0.80 CRBN (0.41) DGAT1LMNARAB9ACRBN
SCHEMBL13719516 0.79 PTPN1 (0.41) LMNACSNK1A1CRBNDEGS1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885LMNA 2193/4885RAB9A 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.